APA Takeaways: Former Sanofi Exec Reflects On DSM-5, Eroom’s Law And More
The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.
You may also be interested in...
Alkermes’ focus on mental illnesses, substance abuse and other CNS disorders could gain a boost from essential health benefit and mental health parity provisions of the law.
Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.
“Everything that applies to pharma in general is magnified in neuroscience because the timelines are compressed and the punishment for failure is greater,” industry consultant Harry Tracy said at the Therapeutic Area Partnerships meeting.